Trial · NCT03070730
Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist
NCT03070730, Phase 1, Phase 2, Terminated, Beth Israel Deaconess Medical Center; results first posted 2017-05-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist. Trials, record NCT03070730. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03070730
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist
- NCT number
- NCT03070730
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
- Interventions
- Droxidopa, Atenolol, Placebos
- First posted
- 2017-03-06
- Last updated
- 2017-05-18
- Results first posted
- 2017-05-18
- Limitations and caveats
- The trial was terminated early due to difficulties in the recruitment process. Subjects were found to be ineligible, or decided not to participate in the study.
Source ClinicalTrials.gov
Registered outcomes42
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Maximal Postural Tachycardia During Tilt | Up to 3 days after randomization | Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. |
| Primary | Change Maximal Postural Tachycardia During Tilt | 2 weeks after first intervention | Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. |
| Primary | Change Maximal Postural Tachycardia During Tilt | 2 weeks after second intervention | Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. |
| Primary | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | up to 3 days after randomization | A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. |
| Primary | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | 2 weeks after first intervention | A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. |
| Primary | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | 2 weeks after second intervention | A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. |
| Secondary | Change in Blood Pressure From Baseline | 1 week after first intervention | |
| Secondary | Change in Blood Pressure From Baseline | 1 week after second intervention | |
| Secondary | Change in Blood Pressure From Baseline | 1 week after third intervention | |
| Secondary | Change in Heart Rate From Baseline | 1 week after first intervention |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 registered outcomesOutcomes42
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Maximal Postural Tachycardia During Tilt | Up to 3 days after randomization | |||
| PRIMARY | Change Maximal Postural Tachycardia During Tilt | 2 weeks after first intervention | |||
| PRIMARY | Change Maximal Postural Tachycardia During Tilt | 2 weeks after second intervention | |||
| PRIMARY | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | up to 3 days after randomization | |||
| PRIMARY | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | 2 weeks after first intervention | |||
| PRIMARY | Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | 2 weeks after second intervention | |||
| SECONDARY | Change in Blood Pressure From Baseline | 1 week after first intervention | |||
| SECONDARY | Change in Blood Pressure From Baseline | 1 week after second intervention | |||
| SECONDARY | Change in Blood Pressure From Baseline | 1 week after third intervention | |||
| SECONDARY | Change in Heart Rate From Baseline | 1 week after first intervention |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 outcomesResults by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Maximal Postural Tachycardia During Tilt | Atenolol | 0 | |||
| Change in Maximal Postural Tachycardia During Tilt | Placebos | 0 | |||
| Change in Maximal Postural Tachycardia During Tilt | Droxidopa | 0 | |||
| Change Maximal Postural Tachycardia During Tilt | Atenolol | 0 | |||
| Change Maximal Postural Tachycardia During Tilt | Placebos | 0 | |||
| Change Maximal Postural Tachycardia During Tilt | Droxidopa | 0 | |||
| Change Maximal Postural Tachycardia During Tilt | Atenolol | 0 | |||
| Change Maximal Postural Tachycardia During Tilt | Placebos | 0 | |||
| Change Maximal Postural Tachycardia During Tilt | Droxidopa | 0 | |||
| Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline | Atenolol | 0 |
1 to 10 of 126Source ClinicalTrials.gov
See all 126 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atenolol | 0 | |
| Overall Study | STARTED | Placebos | 0 | |
| Overall Study | STARTED | Droxidopa | 0 | |
| Overall Study | COMPLETED | Atenolol | 0 | |
| Overall Study | COMPLETED | Placebos | 0 | |
| Overall Study | COMPLETED | Droxidopa | 0 | |
| Overall Study | NOT COMPLETED | Atenolol | 0 | |
| Overall Study | NOT COMPLETED | Placebos | 0 | |
| Overall Study | NOT COMPLETED | Droxidopa | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atenolol | 0 | 0 |
| Total, all-cause mortality | Placebos | 0 | 0 |
| Total, all-cause mortality | Droxidopa | 0 | 0 |
| Total, other adverse events | Atenolol | 0 | 0 |
| Total, other adverse events | Placebos | 0 | 0 |
| Total, other adverse events | Droxidopa | 0 | 0 |
| Total, serious adverse events | Atenolol | 0 | 0 |
| Total, serious adverse events | Placebos | 0 | 0 |
| Total, serious adverse events | Droxidopa | 0 | 0 |
Source ClinicalTrials.gov
Papers24
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HL059459 | Orthostatic Intolerance in CFS | FREEMAN, ROY | BETH ISRAEL DEACONESS MEDICAL CENTER | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 1998 to 2011 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03070730
GET https://conductscience.org/api/trials/v1/NCT03070730/registered?page=2